Emcure Pharmaceuticals · NSE: EMCURE · BSE: 544210
Q3 FY26 results · Oct–Dec 2025
Emcure Pharmaceuticals reported revenue from operations of ₹2,363.48 crore (up 20.4% from Q3 FY25) and net profit of ₹231.37 crore (up 48.2% from Q3 FY25) for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 2,363.48 | 1,962.63 | +20.4% | 2,269.82 | +4.1% |
| Other income | 1.85 | 3.90 | −52.4% | 3.12 | −40.7% |
| Total income | 2,365.33 | 1,966.53 | +20.3% | 2,272.95 | +4.1% |
| Profit before tax | 313.79 | 229.92 | +36.5% | 341.42 | −8.1% |
| Net profit for the period | 231.37 | 156.09 | +48.2% | 251.37 | −8.0% |
| Attributable to shareholders of the company | 230.54 | 153.72 | +50.0% | 243.46 | −5.3% |
| EPS, basic (₹) | 12.16 | 8.12 | +49.8% | 12.85 | −5.4% |
| Net margin (%) | 9.8 | 8.0 | 11.1 |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,418.31 | 1,028.81 | +37.9% | 1,260.60 | +12.5% |
| Other income | 138.30 | 19.41 | +612.5% | 22.75 | +507.8% |
| Total income | 1,556.61 | 1,048.22 | +48.5% | 1,283.36 | +21.3% |
| Profit before tax | 314.37 | 67.25 | +367.4% | 157.89 | +99.1% |
| Net profit for the period | 258.85 | 50.20 | +415.6% | 117.62 | +120.1% |
| EPS, basic (₹) | 13.65 | 2.65 | +415.1% | 6.21 | +119.8% |
| Net margin (%) | 18.3 | 4.9 | 9.3 |
Consolidated
- Filed with BSE
- 04 Feb 2026, 14:45 IST
- Board meeting
- 04 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 04 Feb 2026, 14:45 IST
- Board meeting
- 04 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE